Scholar Rock (SRRK) Competitors

$51.28 +1.11 (+2.21%)

Closing price 04:00 PM Eastern

Extended Trading

$51.31 +0.03 (+0.06%)

As of 06:18 PM Eastern

SRRK vs. ROIV, MRNA, VTRS, GMAB, and RGC

Should you buy Scholar Rock stock or one of its competitors? MarketBeat compares Scholar Rock with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Scholar Rock include Roivant Sciences (ROIV), Moderna (MRNA), Viatris (VTRS), Genmab A/S (GMAB), and Regencell Bioscience (RGC). These companies are all part of the "pharmaceutical products" industry.

How does Scholar Rock compare to Roivant Sciences?

Scholar Rock (NASDAQ:SRRK) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

91.1% of Scholar Rock shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 13.3% of Scholar Rock shares are owned by company insiders. Comparatively, 10.8% of Roivant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Scholar Rock presently has a consensus price target of $56.00, indicating a potential upside of 9.20%. Roivant Sciences has a consensus price target of $30.55, indicating a potential upside of 3.56%. Given Scholar Rock's stronger consensus rating and higher probable upside, equities analysts clearly believe Scholar Rock is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	5 Strong Buy rating(s)	3.17
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Scholar Rock had 16 more articles in the media than Roivant Sciences. MarketBeat recorded 24 mentions for Scholar Rock and 8 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.76 beat Scholar Rock's score of 0.70 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	9 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Scholar Rock has a net margin of 0.00% compared to Roivant Sciences' net margin of -6,079.94%. Roivant Sciences' return on equity of -19.04% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
Roivant Sciences	-6,079.94%	-19.04%	-18.15%

Scholar Rock has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market.

Roivant Sciences has higher revenue and earnings than Scholar Rock. Roivant Sciences is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
Roivant Sciences	$29.05M	726.79	-$171.98M	-$1.17	N/A

Summary

Scholar Rock beats Roivant Sciences on 9 of the 16 factors compared between the two stocks.

How does Scholar Rock compare to Moderna?

Scholar Rock (NASDAQ:SRRK) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

In the previous week, Moderna had 9 more articles in the media than Scholar Rock. MarketBeat recorded 33 mentions for Moderna and 24 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 0.70 beat Moderna's score of 0.65 indicating that Scholar Rock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	9 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	19 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

Scholar Rock has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
Moderna	-143.55%	-26.64%	-19.32%

Scholar Rock has higher earnings, but lower revenue than Moderna. Scholar Rock is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
Moderna	$2.20B	9.01	-$2.82B	-$8.15	N/A

91.1% of Scholar Rock shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 13.3% of Scholar Rock shares are owned by company insiders. Comparatively, 10.8% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Scholar Rock presently has a consensus price target of $56.00, indicating a potential upside of 9.20%. Moderna has a consensus price target of $35.73, indicating a potential downside of 28.58%. Given Scholar Rock's stronger consensus rating and higher possible upside, equities research analysts plainly believe Scholar Rock is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	5 Strong Buy rating(s)	3.17
Moderna	5 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.84

Scholar Rock has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market. Comparatively, Moderna has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

Summary

Scholar Rock beats Moderna on 10 of the 16 factors compared between the two stocks.

How does Scholar Rock compare to Viatris?

Scholar Rock (NASDAQ:SRRK) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

91.1% of Scholar Rock shares are owned by institutional investors. Comparatively, 79.9% of Viatris shares are owned by institutional investors. 13.3% of Scholar Rock shares are owned by company insiders. Comparatively, 0.3% of Viatris shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Scholar Rock presently has a consensus price target of $56.00, indicating a potential upside of 9.20%. Viatris has a consensus price target of $15.71, indicating a potential downside of 8.96%. Given Scholar Rock's stronger consensus rating and higher possible upside, equities research analysts plainly believe Scholar Rock is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	5 Strong Buy rating(s)	3.17
Viatris	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

In the previous week, Scholar Rock had 9 more articles in the media than Viatris. MarketBeat recorded 24 mentions for Scholar Rock and 15 mentions for Viatris. Scholar Rock's average media sentiment score of 0.70 beat Viatris' score of 0.64 indicating that Scholar Rock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	9 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viatris	2 Very Positive mention(s)	6 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Scholar Rock has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
Viatris	-2.04%	19.04%	7.62%

Scholar Rock has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
Viatris	$14.56B	1.38	-$3.51B	-$0.26	N/A

Scholar Rock has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market. Comparatively, Viatris has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

Summary

Scholar Rock beats Viatris on 11 of the 16 factors compared between the two stocks.

How does Scholar Rock compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

In the previous week, Scholar Rock had 15 more articles in the media than Genmab A/S. MarketBeat recorded 24 mentions for Scholar Rock and 9 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.71 beat Scholar Rock's score of 0.70 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	1 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	9 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 91.1% of Scholar Rock shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 13.3% of Scholar Rock shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Genmab A/S presently has a consensus target price of $39.07, indicating a potential upside of 45.25%. Scholar Rock has a consensus target price of $56.00, indicating a potential upside of 9.20%. Given Genmab A/S's higher possible upside, analysts plainly believe Genmab A/S is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.83
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	5 Strong Buy rating(s)	3.17

Genmab A/S has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	4.51	$963M	$1.32	20.38
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

Genmab A/S has a net margin of 21.05% compared to Scholar Rock's net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
Scholar Rock	N/A	-163.52%	-96.67%

Genmab A/S has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market.

Summary

Genmab A/S beats Scholar Rock on 10 of the 16 factors compared between the two stocks.

How does Scholar Rock compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Scholar Rock (NASDAQ:SRRK) are both pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

In the previous week, Regencell Bioscience had 4 more articles in the media than Scholar Rock. MarketBeat recorded 28 mentions for Regencell Bioscience and 24 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 0.70 beat Regencell Bioscience's score of 0.02 indicating that Scholar Rock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	2 Positive mention(s)	21 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral
Scholar Rock	9 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Regencell Bioscience's return on equity of 0.00% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Scholar Rock	N/A	-163.52%	-96.67%

Scholar Rock has a consensus target price of $56.00, indicating a potential upside of 9.20%. Given Scholar Rock's stronger consensus rating and higher probable upside, analysts clearly believe Scholar Rock is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	5 Strong Buy rating(s)	3.17

0.1% of Regencell Bioscience shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 2.0% of Regencell Bioscience shares are held by insiders. Comparatively, 13.3% of Scholar Rock shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Regencell Bioscience has a beta of 1.88, meaning that its share price is 88% more volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market.

Summary

Scholar Rock beats Regencell Bioscience on 7 of the 12 factors compared between the two stocks.

Get Scholar Rock News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRRK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SRRK vs. The Competition

Export

Metric	Scholar Rock	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.14B	$3.40B	$6.29B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-14.28	18.98	20.89	25.59
Price / Sales	N/A	176.16	522.17	62.83
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	22.30	6.74	9.86	6.70
Net Income	-$377.94M	$24.11M	$3.55B	$333.77M
7 Day Performance	10.40%	0.06%	-0.32%	0.45%
1 Month Performance	3.49%	0.81%	1.33%	4.06%
1 Year Performance	67.91%	78.08%	41.10%	36.24%

Scholar Rock Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SRRK Scholar Rock	2.0148 of 5 stars	$51.28 +2.2%	$56.00 +9.2%	+59.8%	$6.14B	N/A	N/A	140	Earnings Report Analyst Revision
ROIV Roivant Sciences	2.3431 of 5 stars	$28.36 +1.9%	$30.55 +7.7%	+171.6%	$19.92B	$29.05M	N/A	860	Positive News Gap Up
MRNA Moderna	1.4787 of 5 stars	$47.30 +4.3%	$35.73 -24.5%	+97.8%	$17.92B	$1.94B	N/A	4,700
VTRS Viatris	2.5693 of 5 stars	$15.20 +1.1%	$14.67 -3.5%	+97.6%	$17.51B	$14.30B	N/A	30,000	Earnings Report
GMAB Genmab A/S	4.3035 of 5 stars	$27.04 +2.2%	$39.07 +44.5%	+37.5%	$16.49B	$3.72B	17.45	3,029

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SRRK) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Scholar Rock (SRRK) Competitors

SRRK vs. ROIV, MRNA, VTRS, GMAB, and RGC

How does Scholar Rock compare to Roivant Sciences?

Summary

How does Scholar Rock compare to Moderna?

Summary

How does Scholar Rock compare to Viatris?

Summary

How does Scholar Rock compare to Genmab A/S?

Summary

How does Scholar Rock compare to Regencell Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRRK vs. The Competition

Scholar Rock Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Scholar Rock (SRRK) Competitors

SRRK vs. ROIV, MRNA, VTRS, GMAB, and RGC

How does Scholar Rock compare to Roivant Sciences?

Do institutionals and insiders believe in SRRK or ROIV?

Do analysts recommend SRRK or ROIV?

Does the media refer more to SRRK or ROIV?

Is SRRK or ROIV more profitable?

Which has more volatility & risk, SRRK or ROIV?

Which has higher earnings and valuation, SRRK or ROIV?

Summary

How does Scholar Rock compare to Moderna?

Does the media refer more to SRRK or MRNA?

Is SRRK or MRNA more profitable?

Which has better earnings & valuation, SRRK or MRNA?

Do insiders & institutionals believe in SRRK or MRNA?

Do analysts recommend SRRK or MRNA?

Which has more risk & volatility, SRRK or MRNA?

Summary

How does Scholar Rock compare to Viatris?

Do insiders & institutionals believe in SRRK or VTRS?

Do analysts recommend SRRK or VTRS?

Does the media refer more to SRRK or VTRS?

Is SRRK or VTRS more profitable?

Which has better earnings & valuation, SRRK or VTRS?

Which has more risk & volatility, SRRK or VTRS?

Summary

How does Scholar Rock compare to Genmab A/S?

Does the media prefer GMAB or SRRK?

Do institutionals & insiders believe in GMAB or SRRK?

Do analysts prefer GMAB or SRRK?

Which has preferable valuation and earnings, GMAB or SRRK?

Is GMAB or SRRK more profitable?

Which has more volatility and risk, GMAB or SRRK?

Summary

How does Scholar Rock compare to Regencell Bioscience?

Which has better valuation & earnings, RGC or SRRK?

Does the media prefer RGC or SRRK?

Is RGC or SRRK more profitable?

Do analysts prefer RGC or SRRK?

Do institutionals & insiders believe in RGC or SRRK?

Which has more volatility & risk, RGC or SRRK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRRK vs. The Competition

Scholar Rock Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools